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HuR-targeted small molecule 
inhibitor exhibits cytotoxicity 
towards human lung cancer cells
Ranganayaki Muralidharan1,4, Meghna Mehta2,4, Rebaz Ahmed1,5, Sudeshna Roy6, Liang Xu7, 
Jeffrey Aubé6, Allshine Chen3, Yan Daniel Zhao3,4, Terence Herman3,4, Rajagopal Ramesh  1,4,5 
& Anupama Munshi2,4
Human antigen (Hu) R is an RNA-binding protein whose overexpression in human cancer correlates 
with aggressive disease, drug resistance, and poor prognosis. HuR inhibition has profound anticancer 
activity. Pharmacologic inhibitors can overcome the limitations of genetic inhibition. In this study, we 
examined the antitumor activity of CMLD-2, a small-molecule inhibitor directed against HuR, using 
non-small cell lung cancer (NSCLC) as a model. CMLD-2 efficacy was tested in vitro using H1299, A549, 
HCC827, and H1975 NSCLC cells and MRC-9 and CCD-16 normal human fibroblasts. Treatment of 
NSCLC cells with CMLD-2 produced dose-dependent cytotoxicity, caused a G1 phase cell-cycle arrest 
and induced apoptosis. CMLD-2 decreased HuR mRNA and the mRNAs of HuR-regulated proteins (Bcl2 
and p27) in tumor cells. Additionally, reduction in the expression of HuR, Bcl2, cyclin E, and Bcl-XL with 
increased expression of Bax and p27 in CMLD-2-treated NSCLC cells were observed. CMLD-2-treated 
normal cells, HuR-regulated mRNAs and proteins albeit showed some reduction were less compared 
to tumor cells. Finally, CMLD-2 treatment resulted in greater mitochondrial perturbation, activation of 
caspase-9 and -3 and cleavage of PARP in tumor cells compared to normal cells. Our proof-of concept 
study results demonstrate CMLD-2 represents a promising HuR-targeted therapeutic class that 
with further development could lead to advanced preclinical studied and ultimately for lung cancer 
treatment.
HuR is an RNA-binding protein that regulates the stability and transcription of numerous mRNAs whose 
protein products function as oncoproteins and are frequently overexpressed in several human cancers, 
including lung cancer1–3. HuR overexpression has been correlated with aggressive disease and poor 
prognosis4–10. Preclinical studies have demonstrated that HuR promotes tumor cell proliferation, migration, 
angiogenesis, and metastasis11–14. Further, HuR overexpression has been reported to contribute to drug 
resistance15–17. Results from these preclinical and clinical studies suggest that HuR may be a molecular target for 
cancer therapy and that suppression of HuR will likely result in tumor growth inhibition and anticancer activity.
Studies from our laboratory and others have previously shown that inhibition of HuR expression by gene 
silencing inhibited cell proliferation, migration, invasion, angiogenesis, and metastasis in a broad spectrum of 
human cancer cells11–14, 18–22. These studies utilized anti-sense oligonucleotide or small interfering (si) RNA to 
inhibit HuR. While these results established proof-of-concept, there are several barriers, such as poor cell uptake 
and low serum stability, to siRNA-based therapy. Another challenge is the availability of a delivery vehicle that 
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can efficiently deliver the HuR-targeted si/shRNA, oligonucleotide, or plasmid DNA to tumor depots and pro-
duce considerable anticancer activity. While several formulations for siRNA delivery have been developed and 
tested, each of the formulations has its limitations23–26. Thus, approaches that utilize genetic inhibition for cancer 
treatment often suffer from issues related to inefficient drug delivery to tumor tissues, thus limiting their clinical 
translation.
More recently, we developed and tested tumor-targeted nanoparticle delivery of HuRsiRNA (HuR-NP) in 
lung cancer, and showed significant antitumor activity in vitro and in vivo. The combination of HuR-NP with 
a CXCR4 inhibitor produced enhanced inhibition of lung tumor cell migration and invasion26. Similarly, HuR 
siRNA therapy combined with ionizing radiation resulted in significant radiosensitization of triple-negative 
breast cancer (TNBC) cells27. Consistent with our results, other laboratories have reported similar treatment 
outcomes with HuR siRNA11–14, 28. While all of these studies are promising, advancing siRNA-based therapy to 
the clinic remains a challenge. The availability of a pharmacologic inhibitor directed against HuR, however, offers 
advantages over siRNA based therapies and can be rapidly tested and advanced for clinical studies. Blanco et al.29, 
using MS-444, an HuR-targeted inhibitor, showed antitumor activity against colorectal cancer both in vitro and 
in vivo. Concurring with these findings, Romeo et al.30, showed MS-444 treatment reverted TRAIL resistance in 
pancreatic cancer. Both studies provide evidence that small molecule inhibitors can successfully disrupt HuR and 
produce anticancer activity. More recently, Wu et al.31, reported the development of a small molecule inhibitor 
(CMLD-2) that disrupts the interaction between HuR protein and its target mRNA.
CMLD-2 is a coumarin-derived molecule that was identified through fluorescence polarization (FP) 
assay-based high throughput screening (HTS) of a library of 6,000 compounds developed by the Kansas 
University Chemical Methodologies and Library Development (CMLD) center (www.cmld.ku.edu)31. The cou-
marin and dihydrocouramin-scaffold containing compounds (such as CMLD-2 and ita analogues) were devel-
oped by Tunge and co-workers using TFA-mediated hydroarylation chemistry and added to the in-house CMLD 
library for subsequent screening against various therapeutic targets32. CMLD-2 was demonstrated to efficiently 
disrupt the interaction between HuR protein and adenine and uridine-rich elements (ARE) oligo from Musashi 
RNA binding protein 1 (Msi1) at nanomolar concentrations31. Musashi is a known target of HuR33. CMLD-2 
exhibited enhanced cytotoxicity towards HCT-116 colon and MiaPaCa2 pancreatic cancer cells and had an IC50 
of 28.9 µM and 18.2 µM respectively. Accompanied with the cytotoxicity in HCT-116 cells was the reduction 
in mRNA and protein expression of Bcl-2, Msi1 and XIAP with concomitant increase in capase-3 and PARP 
cleavage and LC3I/II conversion indicating involvement of both autophagy and apoptosis-mediated death. In 
contrast, CMLD-2 exhibited reduced cytotoxicity towards normal fibroblast (WI-38; IC50 63.7 µM) and normal 
human colon epithelial (CCD 841 CoN IC50 63.7 µM) cells. The IC50 values for normal cells were approximately 
two-fold higher than for cancer cells. While HuR-targeted small molecule inhibitors such as CMLD-2 have been 
developed and tested in pancreatic and colon cancers, their efficacy against human lung cancer cells is not known.
In the present study, we examined whether pharmacologic inhibition of HuR using the small-molecule inhib-
itor, CMLD-2, would produce antitumor activity in human lung cancer cells. Demonstrating efficacy would pro-
vide a basis for making improvements in CMLD-2 -based cancer therapy.
Materials and Methods
Chemistry. CMLD-2 was prepared as previously reported31. The compound was dissolved in DMSO and 
used in the studies described herein. DMSO without the compound was used as drug carrier control in all of the 
studies.
Cell lines and cell culture. Human non-small cell lung cancer (NSCLC) cells H1299, A549, HCC827, and 
H1975 and normal human lung fibroblasts MRC-9 and CCD16 were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). Cell lines were authenticated via STR profiling prior to initiating experiments. 
Tumor cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich, St. 
Louis, MO) and 1% penicillin/streptomycin. Normal human lung fibroblasts were cultured in EMEM with 10% 
fetal bovine serum (FBS; Sigma) and 1% penicillin/streptomycin.
Cell viability assay. Cells (1 × 105) were seeded in six-well plates in the appropriate culture medium con-
taining 10% FBS. After 24 h of incubation, medium was replaced with fresh culture medium containing DMSO 
(drug carrier) or CMLD-2 (20 or 30 µM). At 24 h and 48 h after treatment, cells were harvested and cell viability 
was determined using trypan blue exclusion assay as previously described20, 26. The inhibitory activity of CMLD-2 
was tested in duplicate well for each cell line and the experiment repeated three separate times. The data shown is 
representative of one experiment.
Western blotting. Total cell lysates prepared from DMSO- and CMLD-2-treated cells were subjected to 
western blot analysis as previously described20, 34, 35. Primary antibodies against human HuR, Bcl2, Cyclin E, 
and p27 (Santa Cruz Biotechnology, Dallas, TX); BAX, Bcl-XL, caspase-3, caspase-9, and PARP (Cell Signaling, 
Cambridge, MA); and beta-actin (Sigma Chemicals) were purchased and used as recommended by the manu-
facturer. Appropriate horseradish peroxidase- (HRP)-tagged secondary antibodies (Santa Cruz Biotechnology, 
Inc., and Jackson Immuno-Research Laboratories, Inc., West Grove, PA) was used. Proteins were detected using 
an enhanced chemiluminescence kit (Thermo Scientific) on a chemiluminescence imaging system (Syngene, 
Frederick, MD) and the relative protein expression compared to beta-actin was quantified using Gene tools soft-
ware (Syngene), as previously described20, 36.
Quantitative real-time polymerase chain reaction (qRT-PCR). qRT-PCR assay was performed as 
previously described26, 27, 36. Briefly, H1299 cells were collected and total RNA from DMSO- and CMLD-2-treated 
cells was isolated using TRIZOL (Invitrogen, Grand Island NY) reagent according to the manufacturer’s protocol. 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 9694  | DOI:10.1038/s41598-017-07787-4
From the 2 µg of total RNA, first-strand complementary (c) DNA was synthesized with a Quant script cDNA 
synthesis kit (Bio-Rad, Richmond CA). The cDNA was subsequently used to perform qRT-PCR (Bio-Rad CFX96 
Touch Real-Time PCR Detection System) with SYBR chemistry using iQTM SYBR Green super mix (Bio-Rad). 
The oligonucleotide primers specific for HuR have been previously described26, 27. The relative gene expression 
values were quantified as previously described26, 27. Experiment was conducted two separate times and the data 
obtained was analyzed for statistical significance. Data shown is from one of the two experiments.
Cell cycle analysis. Cells (H1299, A549, MRC-9, CCD16; 1 × 105/well) were treated with CMLD-2 for 24 h 
and 48 h following which they were harvested, stained with propidium iodide, and subjected to flow-cytometric 
analysis as described previously20, 37, 38. Cells treated with rapamycin (100 nM) served as positive control39. Cells 
treated with DMSO alone served as controls.
Annexin V assay. H1299, A549, MRC-9 and CCD16 cells (1 × 105/well) seeded in six-well plates were 
treated with CMLD-2 (30 µM) and stained with annexin V conjugated to fluorescein isothiocyanate (FITC) and 
propidium iodide (PI) using a Dead cell apoptosis kit (Molecular probes) according to manufacturer’s protocol. 
Cells treated with cisplatin (30 µM) served as positive control for the assay. Briefly, cells were harvested at 24 h and 
48 h after treatment and suspended in annexin V binding buffer at a concentration of 1 × 105 cells/ml. 100 µl of the 
cell suspension was incubated with 5 µl of annexin V FITC and 1 µl of 100 µg/ml PI. After 15 min of incubation at 
room temperature, the number of viable (annexin V- and PI-negative), early apoptotic (annexin V-positive and 
PI-negative), and dead (annexin V- and PI-positive) cells were determined with a FACSCalibur flow cytometer 
using the Cell Quest software (BD Biosciences) at excitation 488 nm and emission 530 nm. Results were plotted as 
the percentage of cells undergoing apoptosis at the two time points tested and subjected to statistical analysis. The 
apoptotic activity of CMLD-2 against each cell line was tested two separate times for reproducibility and statistical 
analysis. The data shown is representative of one experiment.
Figure 1. Human lung tumor (H1299, A549) and normal lung fibroblast (CCD16, MRC-9) cell lines were 
treated with either DMSO or CMLD-2 (20 or 30 µM). Cytotoxicity was measured at 24 h and 48 h after 
treatment. Error bar denotes SD; NS not significant; *p < 0.05; **p < 0.001.
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Mitochondrial perturbation assay. H1299, A549, and MRC-9 cells (5 × 104 cells/ well) seeded in cham-
ber slides were treated with DMSO and CMLD-2 (30 µM). Cells treated with valinomycin (30 µM; Cayman, Ann 
Arbor, MI) served as positive control40. After 24 h and 48 h of treatment, cells were stained using the cationic dye 
JC-1 (Sigma Aldrich) as described previously27, 34. Briefly, the cells were incubated with JC-1 staining solution for 
20 min at 37 °C. At the end of the incubation period, the staining solution was aspirated and cells were washed 
twice with culture medium. Cells were subsequently overlaid with fresh culture medium and observed under an 
inverted Leica SP2 MP confocal microscope (Leica Microsystems, Buffalo Grove, IL). Based on the changes in the 
membrane potential, the presence of JC-1 aggregates and JC-1 monomers was determined by excitation/emission 
at 525 nm/590 nm and 490 nm/530 nm, respectively. The quantitative difference in membrane potential was meas-
ured by determining the ratio of green over red fluorescence intensity and analyzed for statistical significance.
Statistical analysis. All of the experiments were conducted two or more times and the data obtained for 
each of the study was subjected to statistical analysis. The SAS 9.2 software was used for statistical analyses. The 
results are presented as mean ± standard deviation (SD). Univariate statistical significance was determined by 
one-way analysis of variance (ANOVA) with Tukey’s adjustment for pairwise comparisons. Differences between 
groups were obtained using a linear mixed effects model with Tukey’s adjustment. A P value of less than 0.05 was 
considered statistically significant.
Data availability statement. All data generated or analyzed during this study are included in this pub-
lished article (and its Supplementary Information files).
Results
CMLD-2 preferentially inhibits lung tumor growth. Initial studies were focused on testing the cyto-
toxic concentration of CMLD-2 that was effective in suppressing tumor cell growth. A panel of NSCLC cells 
(H1299, A549, HCC827, H1975) was treated with 20 and 30 µM concentrations of CMLD-2 for 24 h and 48 h. A 
dose-dependent inhibition in cell viability was observed in all four CMLD-2 -treated cell lines compared with 
DMSO-treated control cells [Fig. 1A,B; p < 0.05; Supplementary Figure S1A,B; p < 0.05]. Treatment with 30 µM 
of CMLD-2, however, produced the greatest inhibition at the two time points tested. Based on this result, all sub-
sequent studies were conducted with 30 µM CMLD-2.
Both the normal lung fibroblast cell lines (CCD16 and MRC-9) were less responsive and showed markedly 
less growth inhibition after CMLD-2 treatment (25–28% inhibition) than the tumor cells (45–67%; Fig. 1C,D).
CMLD-2 treatment reduces expression of HuR and HuR-regulated mRNAs and proteins. It 
has been previously shown that genetic knockdown of HuR results in attenuation of HuR mRNA and protein 
expression14, 20, 27, 41–44. To determine whether CMLD-2 treatment produced a similar reduction in HuR mRNA 
and protein expression, H1299 cells were treated with 30 μM CMLD-2 for 24 h and 48 h. A significant reduc-
tion in HuR and Bcl-2 mRNA expression, with a concomitant increase in p27 mRNA expression, was observed 
(Fig. 2; p < 0.05). Diminished protein expression of HuR, Bcl-2, Cyclin E and Bcl-XL, and increased expres-
sion of p27 and BAX, were associated with HuR mRNA reduction (Fig. 3A; p < 0.05). A similar change in the 
expression of these proteins was observed in CMLD-2-treated A549 (Fig. 3B; p < 0.05), H1975, and HCC827 cells 
Figure 2. H1299 cells were treated with either DMSO or 30 μM CMLD-2 and the mRNA levels of HuR and 
HuR-regulated markers Bcl-2 and p27 were measured by RT-PCR. Error bar denotes SD; *p < 0.05; **p < 0.001.
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(Supplementary Figures S2 and S3; p < 0.05). In normal cells, although CMLD-2 treatment produced changes in 
the expression of HuR and HuR-regulated proteins, the reduction was relatively less than that observed for tumor 
cells (Fig. 3C,D).
CMLD-2 induces G1 cell cycle arrest. Since CMLD-2 treatment altered the expression of cell cycle pro-
teins, such as p27 and cyclin E, we evaluated cell cycle profiles in tumor and normal cells. As shown in Fig. 4, a 
marked increase in the G1 phase of cell cycle was observed in both tumor and normal cells. However, the increase 
was greater in tumor cells than in normal cells at the two time points tested. In CMLD-2 -treated H1299 cells, an 
increase of 23% and 27% was observed at 24 h and 48 h, compared with DMSO-treated control cells. In CMLD-2 
-treated A549 cells, the increase was 17% and 22% over DMSO-treated control cells. In CMLD-2 -treated MRC-9 
cells, 14% and 6% increases over controls were observed. The increase in G1 phase of cell cycle in CCD16 cells 
was only 5% at the two time-points tested. In all cell lines, rapamycin treatment used as positive control showed 
maximum G1 cell cycle arrest.
Figure 3. Expression of HuR and HuR-regulated proteins in lung tumor (H1299, A549) and normal lung 
fibroblast (CCD16, MRC-9) cells treated with either DMSO or 20 or 30 µM of CMLD-2. Bar graphs represent 
semi-quantitative analysis of the protein expression detected by western blotting. Beta-actin was used as 
internal loading control. Error bar denotes SD; NS not significant; *p < 0.05; **p < 0.001.
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CMLD-2 induces mitochondrial perturbation in tumor cells. Studies have shown that treatment of 
cells with cytotoxic agents induces cell death by perturbing the mitochondria34, 45–47. In the present study, we 
observed an increase in pro-apoptotic Bax and a decrease in anti-apoptotic Bcl-XL and Bcl-2 protein expres-
sion (Fig. 3). All of these proteins are known to be localized in the outer mitochondrial membrane; any per-
turbation in the mitochondria results in changes in the expression of these proteins. We therefore investigated 
whether CMLD-2 treatment produced alterations in the mitochondria. As shown in Fig. 5, a remarkable and 
significant increase in mitochondrial perturbation was observed in CMLD-2 -treated H1299 and A549 tumor 
Figure 4. Cell cycle analysis showed that CMLD-2 induced greater G1 phase cell cycle arrest in H1299 and 
A549 cells than in MRC-9 and CCD16 cells at 24 h and 48 h after treatment. Rapamycin-treated cells served as 
positive control. Error bar denotes SD; NS not significant; *p < 0.05; **p < 0.001.
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cells, compared to CMLD-2 -treated MRC-9 cells, at both 24 h and 48 h after treatment (p < 0.05). Increased 
mitochondrial perturbation was also observed in valinomycin-treated tumor cells (Supplementary Figure S4; 
p < 0.05). Valinomycin is a known inducer of mitochondrial perturbation40. That the low mitochondrial potential 
observed in CMLD-2-treated MRC-9 cells was due to inability of the cells to respond to treatment was eliminated 
by the observed increase in perturbation in valinomycin-treated cells (Supplementary Figure S4; p < 0.05). These 
results clearly demonstrate that tumor cells are more susceptible to mitochondrial perturbation when exposed to 
CMLD-2 than are normal cells.
CMLD-2 treatment activates caspases and induces apoptotic cell death. To establish whether 
the increased expression of pro-apoptotic BAX protein and simultaneous reduction of anti-apoptotic proteins 
Bcl2 and Bcl-XL in CMLD-2-treated tumor cells occurred through apoptosis, we performed western blot anal-
ysis for apoptotic proteins. Marked activation of caspase-9 and -3 was observed in CMLD-2 -treated H1299 
and A549 cells, resulting in cleavage of their substrate, PARP (Fig. 6A,B; p < 0.05). Similar observations were 
made in H1975 and HCC827 cells (Supplementary Figure S5; p < 0.05). Correlating with caspase activation was 
the significant increase in annexin-V-positive staining in CMLD-2 -treated H1299 and A549 cells (Fig. 7A,B,D; 
p < 0.05). In normal (MRC-9 and CCD16) cells, no marked activation of caspase-3, -9 or PARP cleavage was seen 
after CMLD-2 treatment at either time point (Fig. 6A,B). Analysis for annexin-V-positive staining in CMLD-2 
Figure 5. CMLD-2 perturbs the mitochondrial membrane potential in cells. Perturbation of mitochondrial 
membrane potential using JC-1 dye was observed to be greater in CMLD-2 -treated tumor (H1299 and A549) 
cells, compared to normal (MRC-9) cells. MRC-9 cells with high membrane potential show an aggregation 
of fluorescent red dye, whereas the H1299 and A549 cells with low potential display enhanced monomeric 
green fluorescence. Red fluorescence shows aggregation of fluorescent red dye indicating intact mitochondrial 
potential and monomeric green fluorescence indicates perturbation and low mitochondrial potential. Overlay 
image shows the degree of perturbation. Bar graph shows the relative fluorescence intensity in DMSO- and 
CMLD-2-treated cells. Error bar denotes SD; NS not significant; *p < 0.05; **p < 0.001. Scale bar, 200 µM.
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treated MRC-9 cells showed no significant change compared with DMSO-treated control cells (Fig. 7C,D). These 
results demonstrate CMLD-2 treatment increases apoptotic cell death in tumor cells compared to normal cells.
Discussion
HuR, an RNA-binding protein, has been demonstrated to play a role in tumor growth, progression, and metastasis1–14, 48. 
Studies have shown that HuR overexpression in human cancers not only correlates with poor prognosis, but also 
with resistance to therapy, thus establishing HuR as a molecular target for therapy11–17. Earlier studies from our 
laboratory and others have shown that siRNA-/shRNA-based genetic silencing of HuR in a variety of cancer cells 
resulted in inhibition of cell proliferation, reduced cell migration and invasion, and suppression of metastasis7, 18–22. 
While these studies have established the proof-of-concept, advancing HuR siRNA/shRNA gene-based can-
cer therapy has limitations23, 24. An alternate approach is pharmacologic inhibition, which can have sustained 
inhibitory activity and effective anticancer activity. Therefore, in the present study, we tested the efficacy of a 
small-molecule HuR inhibitor, CMLD-2, against human lung cancer cells compared with normal lung fibroblasts.
Our initial studies focused on determining the effective drug concentration, and identified that 30 µM 
CMLD-2 produced the maximum inhibitory effect on human lung cancer cells. Using this concentration in subse-
quent studies, CMLD-2 exhibited preferential cytotoxicity towards non-small cell lung cancer cells (H1299, A549, 
H1975, and HCC827) compared to the normal human fibroblasts (MRC-9 and CCD16). CMLD-2-mediated 
inhibition was accompanied by a G1 phase cell cycle arrest that subsequently led to apoptosis. Molecular 
studies demonstrated that CMLD-2 treatment significantly reduced HuR mRNA and protein expression and 
HuR-regulated oncogenic proteins in tumor cells compared with normal cells. While our results clearly and con-
vincingly demonstrate that CMLD-2 is effective against lung cancer cells, the question of how CMLD-2 targets 
HuR and exhibits selectivity to cancer cells compared to normal cells, when HuR is expressed in both cell 
types, is unclear. Although, Wu et al.31, showed that CMLD-2 exerts its antitumor activity by disrupting the 
interaction between HuR protein and its target mRNAs, the binding affinity to HuR in tumor cells versus 
normal cells have not been studied. While in the present study we have not investigated the mechanism for 
tumor selectivity, we believe that the binding of CMLD-2 to HuR is likely greater in tumor cells, since they 
express relatively higher levels of HuR than do normal cells. Further, tumor cells may be addicted to the sur-
vival signals provided by HuR-regulated oncoproteins. Thus, CMLD-2-mediated suppression of HuR results 
in reduced expression of HuR-regulated oncoproteins, leading to enhanced tumor cell killing compared to 
normal cells.
In a recent study, we showed the siRNA-mediated HuR inhibition combined with radiation produced 
radiosensitization of breast cancer cells27. In that study, we demonstrated that radiosensitization involved 
mitochondrial perturbation and free-radical production that was accompanied by DNA damage. Similar to 
Figure 6. CMLD-2-induced apoptosis was observed in H1299 and A549 cells, but not in MRC-9 cells and 
CCD16. Induction of apoptosis was measured by cleavage of caspase-3, caspase-9, and PARP at 24 and 48 h and 
CCD16 after treatment, compared with DMSO-treated cells. Bar graphs represent semi-quantitative analysis of 
the protein expression detected by western blotting. Beta-actin was used as internal loading control. Error bar 
denotes SD; NS not significant; *p < 0.05; **p < 0.001.
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our previous observations, CMLD-2 treatment also resulted in mitochondrial perturbation that was signif-
icantly higher in H1299 and A549 tumor cells than in normal MRC-9 cells. Our results show that although 
CMLD-2 and HuR specific siRNA operate at two different levels upstream to inhibit HuR, they appear to 
converge on common death signaling pathways downstream resulting in tumor cell killing. While our study 
indicates apoptotic cell death, the report by Wu et al.31, described CMLD-2 treatment induced both auto-
phagy and apoptosis in colon and pancreatic cancer cells. Thus, it is will be of interest to investigate whether 
autophagy occurs in CMLD-2-treated lung cancer cells also. Further, determining whether autophagy in 
CMLD-2 treated lung cells provide survival or death signal will not only increase our understanding of the 
modus operandi of CMLD-2 but likely offer an opportunity to combine CMLD-2 with autophagy inducers to 
produce enhanced anticancer activity.
The ability of CMLD-2 to exhibit profound antitumor activity supports further development of the inhibitor 
that is efficacious at lower drug concentrations in the nanomolar range and that will have clinical relevance. Our 
in vitro results, while promising, warrant testing the in vivo efficacy, pharmacokinetics and pharmacodynamics, 
and toxicity of CMLD-2. Results from in vivo studies will provide an opportunity to develop structure-activity 
relationship (SAR)-based CMLD-2 inhibitors and a strong rationale to develop HuR-targeted small molecule 
therapeutics for treating lung cancer and other solid tumors.
In conclusion, we have established proof-of-concept and shown that CMLD-2 represents a promising 
HuR-targeted therapeutic class for cancer treatment. However, further improvements in CMLD-2 and its ana-
logues that exhibit efficacy at nanomolar concentrations are warranted. The availability of such HuR-targeted 
small molecule therapeutics that highly efficacious at clinically relevant doses will make a significant impact not 
only in lung cancer treatment but also in the treatment of other HuR overexpressing solid tumors.
Figure 7. Annexin V staining demonstrate CMLD-2 treatment induces apoptosis. Flow cytometric analysis 
shows the percentage of apoptotic and necrotic cells (Q1: necrotic; Q2: late apoptotic; Q3: early apoptotic; Q4: 
Live cells) at 24 h and 48 h in CMLD-2 -treated cells. (A) H1299; (B) A549; (C) MRC-9. Induction of apoptosis 
was greater in CMLD-2 -treated H1299 and A549 cells than in CMLD-2 -treated MRC-9 cells. (D) Bar graphs 
represent the percentage of apoptotic cells at 24 h and 48 h after CMLD-2 treatment. Cells treated with cisplatin 
(CDDP) served as positive control for each cell line. Error bar denotes SD; NS not significant; *p < 0.05; 
**p < 0.001.
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